CA2383252A1 - Treatment of cardiovascular related pathologies - Google Patents

Treatment of cardiovascular related pathologies Download PDF

Info

Publication number
CA2383252A1
CA2383252A1 CA002383252A CA2383252A CA2383252A1 CA 2383252 A1 CA2383252 A1 CA 2383252A1 CA 002383252 A CA002383252 A CA 002383252A CA 2383252 A CA2383252 A CA 2383252A CA 2383252 A1 CA2383252 A1 CA 2383252A1
Authority
CA
Canada
Prior art keywords
group
compound
straight
pyridoxal
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383252A
Other languages
English (en)
French (fr)
Inventor
Rajat Sethi
Wasimul Haque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicure International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383252A1 publication Critical patent/CA2383252A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002383252A 1999-08-24 2000-08-24 Treatment of cardiovascular related pathologies Abandoned CA2383252A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15041599P 1999-08-24 1999-08-24
US60/150,415 1999-08-24
PCT/CA2000/001020 WO2001013900A2 (en) 1999-08-24 2000-08-24 Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds

Publications (1)

Publication Number Publication Date
CA2383252A1 true CA2383252A1 (en) 2001-03-01

Family

ID=22534418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383252A Abandoned CA2383252A1 (en) 1999-08-24 2000-08-24 Treatment of cardiovascular related pathologies

Country Status (6)

Country Link
US (7) US6677356B1 (https=)
EP (2) EP1872797A3 (https=)
JP (1) JP2003507418A (https=)
AU (1) AU783855B2 (https=)
CA (1) CA2383252A1 (https=)
WO (1) WO2001013900A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339085B1 (en) * 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001072309A2 (en) * 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
NO20024880L (no) * 2002-03-19 2003-09-22 Per Hamre Sammensetning inneholdende fosfat
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
WO2004084910A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
EP1610783A2 (en) * 2003-03-27 2006-01-04 Medicure Inc. Modulation of cell death
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
DK1643999T3 (da) 2003-06-20 2012-01-02 Nephrogenex Inc Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
US20050209289A1 (en) * 2004-03-16 2005-09-22 Talarico Matthew T Method for vascular dysregulation
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
WO2006005173A1 (en) * 2004-07-09 2006-01-19 Medicure International Inc. Combination therapies employing nicotinic acid derivatives or fibric acid derivatives
CA2575849A1 (en) * 2004-08-10 2006-02-16 Medicure International Inc. Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
JPWO2006028007A1 (ja) * 2004-09-06 2008-05-08 興和株式会社 糸球体疾患治療剤
WO2006056038A1 (en) * 2004-09-24 2006-06-01 Medicure International Inc. Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis
EP1796685A1 (en) * 2004-09-24 2007-06-20 Medicure International Inc. Pyridoxal-5´-phosphate and related compounds in combination with therapeutic cadiovascular compounds for treating angina.
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
EP1827455A1 (en) * 2004-11-26 2007-09-05 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
US20080213364A1 (en) * 2004-11-26 2008-09-04 Medicure International, Inc. Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation
US20060128797A1 (en) * 2004-12-15 2006-06-15 Yanming Wang Method and composition for resuscitation
JP2008526783A (ja) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド トリグリセリドレベルを調節するための化合物及び方法
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
SE529780C2 (sv) * 2005-08-04 2007-11-20 Hexagon Metrology Ab Mätförfarande och mätanordning för användning i mätsystem såsom koordinatmätmaskiner
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
EP1790331A1 (en) * 2005-11-28 2007-05-30 Medicure International Inc. Use of pyridoxal-5-phosphate for the treatment of cardiovascular and related pathologies
AU2007244927B2 (en) 2006-04-24 2012-01-12 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
US20070249562A1 (en) * 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation
WO2007139775A2 (en) * 2006-05-23 2007-12-06 University Of Connecticut N-methanocarba derivatives to treat cardiac diseases
US20110123612A1 (en) * 2008-04-10 2011-05-26 Sung Wuk Kim Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
PL2269063T3 (pl) 2008-04-18 2014-04-30 Critical Care Diagnostics Inc Rokowanie ryzyka głównych niekorzystnych zdarzeń sercowych
MY173823A (en) * 2009-01-23 2020-02-24 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
ES2654363T3 (es) 2010-02-22 2018-02-13 University Of Connecticut Derivados de AMP para tratar enfermedades cardíacas
AU2014361813A1 (en) * 2013-12-13 2016-07-28 Ralph ANKENMAN Compositions and methods for treating dysregulated systems
WO2016046674A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of moderate to severe pain
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107418989A (zh) * 2017-08-21 2017-12-01 浙江工业大学 一种脂肪酶催化在线合成n‑(5‑蔗糖酯戊酰基)美托洛尔的方法
CN108508218A (zh) * 2018-07-09 2018-09-07 复旦大学附属中山医院 晚期糖基化终产物cml作为心肌缺血再灌注损伤的早期诊断标志物及其应用

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3206463A (en) 1965-09-14 Pyridoxine aspartate and its process of preparation
FR846376A (fr) 1938-08-23 1939-09-15 Appareillage de navigation aérienne et de bombardement aérien
DE863754C (de) 1951-04-17 1953-01-19 Gottfried Korbmacher Bodenbremse mit zwischen Rad und Fahrbahn einschiebbaren Bremsschuhen an Kraftfahrzeugen
US2904551A (en) * 1956-11-14 1959-09-15 Merck & Co Inc Chemical compounds and processes of preparing the same
US3282778A (en) * 1960-09-02 1966-11-01 Lohel Mervyn Joseph Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound
GB966805A (en) 1961-05-15 1964-08-19 Merck & Co Inc Process for the preparation of 2-methyl-3-hydroxypyridines
NL120995C (https=) 1962-07-05
FR5552M (https=) 1966-04-28 1967-11-20
FR5801M (https=) 1966-06-27 1968-02-19
GB1228142A (https=) 1967-03-31 1971-04-15
FR6453M (https=) 1967-06-13 1968-11-12
JPS4821959Y1 (https=) 1967-09-04 1973-06-26
DE1767499A1 (de) 1968-05-16 1971-09-09 Merck Patent Gmbh Verfahren zur Herstellung haltbarer Vitaminzubereitungen
ES360566A1 (es) 1968-11-22 1970-10-16 Made Labor Sa Un metodo de obtencion de alfa-cetoglutarato de piridoxina y sus derivados.
GB1236531A (en) 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
JPS4821959B1 (https=) 1969-03-31 1973-07-02
US3910921A (en) 1970-01-08 1975-10-07 Soc D Etudes Prod Chimique Papaverine monopyridoxal phosphate
GB1297080A (https=) 1970-04-17 1972-11-22
FR2101010A1 (en) 1970-08-06 1972-03-31 Lyocentre Sparteine mono-and dipyridoxinates and prepn - as tonics for cardiova disorders
JPS5417130B2 (https=) 1971-12-21 1979-06-27
GB1493993A (en) 1975-05-16 1977-12-07 Howard A Dietary supplement and dietary methods employing said supplement for the treatment of obesity
US4036844A (en) 1972-04-04 1977-07-19 Beecham Group Limited Aryloxypyridines
US4053607A (en) 1972-04-04 1977-10-11 Beecham Group Limited Aryloxypyridine for treating hyperglycaemia
GB1360536A (en) 1972-04-25 1974-07-17 Soc D Etudes Prod Chimique Pyridoxyl-l-aspartic acid salt
BE790118A (fr) 1972-10-09 1973-02-01 Made Labor Sa Derives de l'alpha-cetoglutarate de pyridoxal et de pyridoxamine,
US4032534A (en) 1973-03-22 1977-06-28 Ferlus-Chimie S.A. Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids
FR2255883A1 (en) 1973-12-28 1975-07-25 Centre Etd Ind Pharma Clofibric acid-vitamin B6 compsns. - with synergistic hypocholesterolaemic and normolipaemic activity
FR2275209A1 (fr) 1974-06-21 1976-01-16 Synthelabo Nouveaux esters cetoniques, leurs sels, leur preparation et les medicaments qui les renferment
FR2276048A1 (fr) 1974-06-27 1976-01-23 Synthelabo Nouveaux esters du cyclohexanol, leurs sels, leur preparation et les medicaments qui les renferment
DE2461742C2 (de) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPS5417130Y2 (https=) 1975-01-29 1979-07-03
GB1525885A (en) 1976-05-11 1978-09-20 Soc D Etudes Prod Chimique Vincamine salt of pyridoxal phosphate
JPS5417130A (en) 1977-07-08 1979-02-08 Chugai Pharmaceut Co Ltd Remedy for cardio-vasocular diseases
BE863754A (fr) 1978-02-08 1978-05-29 Dechamps Pierre Nouveaux derives de la vincamine utilisables comme regulateurs de la circulation cerebrale
FR2428640A1 (fr) 1978-06-12 1980-01-11 Parcor Derives de pyridoxine, leur procede de preparation et leur application therapeutique
US4167562A (en) 1978-08-28 1979-09-11 Evers H Ray Method and composition for treating arteriosclerosis
DE2845484A1 (de) 1978-10-19 1980-04-30 Groening Ruediger Verfahren zur erhoehung der biologischen verfuegbarkeit von arzneistoffen
IL62602A (en) 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
GB2075983B (en) * 1980-05-19 1984-05-10 Labaz Nv Pyridoxine derivatives process for preparing them and use in therapeutics
US4753956A (en) * 1981-01-02 1988-06-28 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
IT1141070B (it) 1980-09-22 1986-10-01 Luso Farmaco Inst Impiego dell'alfa-chetoglutarato di piridossina nella profilassi della iperlattacidemia
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4735950A (en) 1983-04-05 1988-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same
IN160104B (https=) 1983-04-05 1987-06-27 Scras
US4515771A (en) 1983-04-11 1985-05-07 Fine Daniel H Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition
GB8330517D0 (en) 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
IT1212792B (it) 1983-11-30 1989-11-30 Egidio Aldo Moja Supplemento dietetico e alimento preconfezionato che lo contiene procedimento di preparazione e metodo di somministrazione
US5272165A (en) 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5130324A (en) 1984-03-19 1992-07-14 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4567179A (en) 1984-10-11 1986-01-28 Pfizer, Inc. Antiinflammatory salts of piroxicam
DE3519693A1 (de) 1985-06-01 1987-01-02 Basf Ag Pyridin-derivate, ihre herstellung und verwendung
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US4735956A (en) 1985-09-13 1988-04-05 Merck & Co., Inc. Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers
US4605741A (en) 1985-11-13 1986-08-12 Lisapharma Spa Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate
DE3634016A1 (de) 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
NZ222664A (en) * 1986-11-29 1990-06-26 Vesta Med Pty Ltd Pharmaceutical compositions containing pyridoxal as a source of vitamin b6
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
DE3705549A1 (de) 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
SE8701662L (sv) 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US5213813A (en) 1987-05-29 1993-05-25 The University Of Vermont Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer
ES2043897T3 (es) 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5254557A (en) 1988-05-09 1993-10-19 Beecham Group P.L.C. Compound and treatment
FR2641189B1 (fr) * 1988-06-20 1991-05-10 Timol Mamoojee Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5001115A (en) 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
GB8918368D0 (en) 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
DE4016963A1 (de) 1990-05-25 1991-11-28 Steigerwald Arzneimittelwerk Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5385937A (en) 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
GB2254556B (en) 1991-04-11 1995-04-12 Fisons Plc Formulations containing linolenic acid
EP0586523A4 (en) 1991-05-15 1995-11-29 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
FR2678622B1 (fr) 1991-07-03 1994-11-18 Adir Nouveaux complexes de vanadium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0746202A4 (en) 1992-01-06 1997-06-25 Health Maintenance Programs COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY
EP0555681A1 (en) * 1992-02-13 1993-08-18 E.R. SQUIBB & SONS, INC. Use of a combination of potassium channel activators and sulfhydryl containing compounds for the manufacture of a medicament for the treatment of ischemia and myocarolial infarct
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
ES2140463T3 (es) 1992-06-12 2000-03-01 Cephalon Inc Prevencion y tratamiento de la neuropatia periferica.
US5330743A (en) 1992-11-12 1994-07-19 Magnetic Research, Inc. Aminosaccharide contrast agents for magnetic resonance images
JPH06172220A (ja) * 1992-12-03 1994-06-21 Upjohn Co:The 虚血性疾患治療用医薬組成物
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
IT1263957B (it) 1993-02-23 1996-09-05 Impiego terapeutico del pirrolidon carbossilato di piridossina
TW268948B (https=) 1993-04-02 1996-01-21 Senju Pharma Co
US5443643A (en) * 1993-04-21 1995-08-22 Axis Usa, Inc. Heatless resin coating system
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
JPH0817174B2 (ja) * 1993-11-10 1996-02-21 キヤノン販売株式会社 絶縁膜の改質方法
DE4344751A1 (de) 1993-12-28 1995-06-29 Carl Heinrich Dr Weischer Neue Vitamin B6-Derivate und deren Herstellung und Verwendung als Arzneimittel und als Kosmetika
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
JP2757775B2 (ja) 1994-05-23 1998-05-25 日本電気株式会社 システム時計整合方式およびシステム時計整合機能付電話交換網
DE4440875A1 (de) * 1994-11-16 1996-06-05 Santrade Ltd Vorrichtung zur Herstellung von Pastillen
EP2301562B1 (en) 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
US5569459A (en) 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5733916A (en) 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5610115A (en) * 1995-07-20 1997-03-11 Samsung General Chemicals Co., Ltd. Organic carrier supported metallocene catalyst for olefin polymerization
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5833998A (en) 1995-11-06 1998-11-10 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5663726A (en) * 1995-12-01 1997-09-02 U.S. Philips Corporation High speed variable-length decoder arrangement with reduced memory requirements for tag stream buffering
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5834446A (en) 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US5770215A (en) 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5888514A (en) 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US6610480B1 (en) 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US6051587A (en) 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US5904090A (en) * 1998-10-01 1999-05-18 Dart Industries Inc. Basket and drive arrangement for salad spinner
US6339085B1 (en) * 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
AU3718501A (en) 2000-02-29 2001-09-12 Medicure Int Inc Cardioprotective phosphonates and malonates
ATE364595T1 (de) * 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
AU2002218002A1 (en) 2000-11-02 2002-05-15 University Of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Also Published As

Publication number Publication date
US20040038945A1 (en) 2004-02-26
EP1210117A2 (en) 2002-06-05
AU6814400A (en) 2001-03-19
US7132430B2 (en) 2006-11-07
AU783855B2 (en) 2005-12-15
US7144892B2 (en) 2006-12-05
US7148233B2 (en) 2006-12-12
EP1872797A2 (en) 2008-01-02
JP2003507418A (ja) 2003-02-25
US7115625B2 (en) 2006-10-03
US20040033990A1 (en) 2004-02-19
US20040033991A1 (en) 2004-02-19
US20040033993A1 (en) 2004-02-19
US7115626B2 (en) 2006-10-03
WO2001013900A2 (en) 2001-03-01
US7125889B2 (en) 2006-10-24
US20040033989A1 (en) 2004-02-19
US6677356B1 (en) 2004-01-13
US20040033992A1 (en) 2004-02-19
WO2001013900A3 (en) 2002-02-07
EP1872797A3 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
AU783855B2 (en) Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
AU763464B2 (en) Pyridoxal analogues for vitamin B-6 disorders
EP1162980B1 (en) Pyridoxine compounds in the treatment of cardiovascular pathologies
CN104619710B (zh) 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯
EP1268498B1 (en) Cardioprotective phosphonates
WO2001003682A2 (en) Use of pyridoxin derivatives for the treatment of diabetes and related complications
WO2007121588A1 (en) Treatment of atrial fibrillation
WO2025162212A1 (zh) 一种药物组合物、器官保存液及其应用
EP1256342B1 (en) Hypoglycemics comprising organic zinc (ii) complexes
CA2254528C (en) Treatment of ischemia reperfusion injury and treatment of cellular dysfunction including arrhythmia and heart failure subsequent to myocardial infarction
EP1640005A2 (en) Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin B6
CN117582422A (zh) 一种含葵花籽油的辅酶q10组合物及其制备工艺
WO2007057181A1 (en) Use of aza-phenylalanine compounds for treating cardiac arrhythmia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued